Xenon Inhalation During Orthopaedic Surgery in Elderly Subjects.
Launched by RIGSHOSPITALET, DENMARK · Sep 16, 2005
Trial Information
Current as of July 02, 2025
Completed
Keywords
ClinConnect Summary
Primary endpoint: - The primary efficacy parameter was a combined score based on the seven variables derived from four validated neuropsychological tests of cognitive function; Visual Verbal Learning test, Concept Shifting test, Stroop Color Word Interference test and Letter Digit Coding test. The parameter was used for comparing changes in test results between the screening and first postoperative follow-up testing for the treatment groups.Secondary endpoints:- Cognitive performance changes from baseline to the first post-operative follow-up judged separately for each of the seven variable...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female subjects ≥ 60 years of age.
- • American Soc. of Anaesthesiologists Physical Status Classification (ASA) I-III status \[27\]
- • Referred for elective orthopaedic knee surgery with an anticipated duration of \> 45 min
- • Expected to remain in hospital for at least 3 days
- • Expected to be able to comply with the study protocol throughout the study period
- • Mini Mental State Examination (MMSE) score \> 23
- • Informed consent given
- Exclusion Criteria:
- • Disease of the CNS (infectious, metabolic, tumours, dementia, epilepsy, major psychiatric disease, confusion/ delirium according to Diagnostic \& Statistical Manual of Mental Disorders (DSM) IV criteria)
- • Contradiction for spinal anaesthesia
- • Contradiction for laryngeal mask
- • Regular use of tranquillisers, or antidepressants, if prescribed by psychiatrist for psychosis or depression
- • Undergone neuropsychological testing within the last year
- • Unable to follow study procedures, illiteracy, or poor comprehension of the language used in the psychometric tests
- • Severe visual or auditory disorder
- • Alcoholism or drug abuse
- • CNS disease BMI \> 35 Inab
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Patients applied
Trial Officials
Lars S Rasmussen, MD PhD
Principal Investigator
Rigshospitalet, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials